Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811561 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT03811561 is a Phase 3 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,500 participants, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT03811561, a Phase 3 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
Study Locations (20)
California
- Southern California Res Ctr - Coronado
- FDRC - Costa Mesa
- Advanced Investigative Medicine, Inc. - Hawthorne
- Diabetes/Lipid Mgmt & Res Ctr - Huntington Beach
- Scripps Whittier Diabetes Inst - La Jolla
- Torrance Clin Res Inst, Inc. - Lomita
- Angel City Research, Inc. - Los Angeles
- Downtown LA Res Ctr. Inc. - Los Angeles
- Riverside University Health System Medical Center - Moreno Valley
- Rancho Cucamonga Clinical Research - Rancho Cucamonga
- Clinical Trials Research_Sacramento_0 - Sacramento
- UCLA Diabetes Center at Santa Monica - Santa Monica
- Coastal Metabolic Research Center - Ventura
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Synexus Rsch /Cnt Phnx Med C - Phoenix
- Del Sol Research Management, LLC - Tucson
- South Arizona VA Healthcare System - Tucson
- Synexus Cln Rsrch Inc - Orange Gro FP - Tucson
Colorado
- Barbara Davis Center - Aurora
- Rocky Mount Reg VA Med-DN - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2027-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03811561
The ClinicalTrials.gov registry entry for NCT03811561 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,481-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (67% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.
NCT03811561 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03811561 about?
NCT03811561 is a clinical study titled "A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes". This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - ...
What is the current status of trial NCT03811561?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2019-05-08. Estimated completion is 2027-11-07.
What conditions does trial NCT03811561 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03811561?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03811561?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03811561 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
-
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.